熊去氧胆酸联合复方甘草酸苷治疗原发性胆汁性肝硬化临床疗效观察  

Observation of clinical effect on Ursodeoxycholic Acid combined with Compound Glycyrrhizin in the treatment of primary biliary cirrhosis

作　　者：邹科文[1] 

机构地区：[1]广东省深圳市宝安区中医院,广东深圳518133

出　　处：《中国医药导报》2011年第36期82-83,共2页China Medical Herald

摘　　要：目的:探讨熊去氧胆酸(UDCA)联合复方甘草酸苷治疗原发性胆汁性肝硬化(PBC)的临床疗效。方法:将42例PBC患者随机分为对照组和治疗组,各21例,对照组给予UDCA治疗,治疗组在对照组用药的基础上给予复方甘草酸苷静滴,4～6周后比较治疗前后及两组临床症状的改善情况及相关生化指标的变化。结果:两组患者治疗后临床症状及相关生化指标均明显改善,且治疗组改善优于对照组,差异有统计学意义(P<0.05)。结论:熊去氧胆酸联合复方甘草酸苷治疗PBC,疗效显著,安全性好,值得在临床推广。Objective：To discuss the clinical effects of Ursodeoxycholic Acid（UDCA） combined with Compound Glycyrrhizin in the treatment of primary biliary cirrhosis（PBC）.Methods：42 patients with PBC were randomly divided into control group and treatment group,with 21 cases in each group.Control group was conducted with UDCA treatment,and the treatment group was compounded Glycyrrhizin infusion based on the treatment of control group.The changes of clinical improved situations and relevant biochemical indicators were compared before and after the treatment between the two groups after 4 to 6 weeks.Results：After the treatment,the clinical situations and relevant biochemical indicators of patients in both groups were obviously improved and the effect of the treatment group was better than that of the control group,the difference was statistically significant（P〈0.05）.Conclusion：The method of UDCA combined with Compound Glycyrrhizin in the treatment of PBC is effective and safe,which is worthy of further promotion in the clinical.

关 键 词：原发性胆汁性肝硬化 熊去氧胆酸 复方甘草酸苷 

分 类 号：R575.2[医药卫生—消化系统]